Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifamurtide added to post-operative chemotherapy for high-risk osteosarcoma
2017-001165-24Phase 2Active
- Sponsor
- Unicancer
- Start
- Apr 2018
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mifamurtide in osteosarcoma (OS) (2 arms), sponsored by Unicancer. Primary endpoint: Event-free survival. Started Apr 2018; status: active.
02
Drugs
mifamurtide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2017-001165-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001165-24.